GlassScriptPhysician profile
Rachel E Resendes
NPI 1760765499
$4,910.28
in general payments reported to CMS, 2019-2025
42 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $405 · 2023: $1,147 · 2024: $1,581 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,141 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.79 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,240.85 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $592.31 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $575.98 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $508.45 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $301.44 | 2021-2025 | Caplyta |
| Corium, LLC | $125.00 | 2022 | |
| Lilly USA, LLC | $118.15 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $114.83 | 2021-2024 | |
| Corcept Therapeutics | $108.38 | 2024-2025 | Korlym |
| Esperion Therapeutics, INC. | $107.79 | 2022-2025 | Nexletol |
| Neuronetics, INC. | $83.38 | 2023 | Neurostar Tms Therapy System |
| Mayne Pharma Commercial LLC | $69.35 | 2025 | |
| Sumitomo Pharma America, INC. | $66.64 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $65.55 | 2025 | Voquezna |
| Lundbeck LLC | $65.26 | 2024-2025 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Resendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.